Co-Authors
This is a "connection" page, showing publications co-authored by Xinyi Xia and Yanju Guo.
Connection Strength
2.069
-
Efficacy and Safety of Tocilizumab Treatment COVID-19 Patients: A Case-Control Study and Meta-Analysis. Infect Dis Ther. 2021 Sep; 10(3):1677-1698.
Score: 0.239
-
Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment. Front Immunol. 2021; 12:598799.
Score: 0.233
-
3044 Cases reveal important prognosis signatures of COVID-19 patients. Comput Struct Biotechnol J. 2021; 19:1163-1175.
Score: 0.232
-
The paradoxical problem with COVID-19 ocular infection: Moderate clinical manifestation and potential infection risk. Comput Struct Biotechnol J. 2021; 19:1063-1071.
Score: 0.232
-
Potential False-Positive and False-Negative Results for COVID-19 IgG/IgM Antibody Testing After Heat-Inactivation. Front Med (Lausanne). 2020; 7:589080.
Score: 0.231
-
Clinical outcomes for COVID-19 patients with diabetes mellitus treated with convalescent plasma transfusion in Wuhan, China. J Med Virol. 2021 04; 93(4):2321-2331.
Score: 0.230
-
Clinical efficacy of convalescent plasma therapy on treating COVID-19 patients: Evidence from matched study and a meta-analysis. Clin Transl Med. 2020 Dec; 10(8):e259.
Score: 0.229
-
Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China 'hot spot' versus in US 'hot spot': similarities and differences. Ann Rheum Dis. 2021 05; 80(5):e63.
Score: 0.222
-
Tumor biomarkers predict clinical outcome of COVID-19 patients. J Infect. 2020 09; 81(3):452-482.
Score: 0.222